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Abstract
Background: Defining environmental factors responsible for development of autoimmunity in rheumatoid arthritis
(RA) is critical for understanding mechanisms of disease initiation and propagation. Notably, a history of cigarette
smoking has been implicated in the genesis of RA and is associated with worse disease outcomes. Antibodies to
peptidylarginine deiminase 4 (PAD4) are also associated with more severe RA. A subset of patients who have PAD4
autoantibodies that cross-react with PAD3 (anti-PAD3/4) are at the highest risk for interstitial lung disease, and this
risk is augmented by a history of cigarette smoking. It is unclear, however, if smoking is etiologically linked to the
development of anti-PAD4 antibodies.
Methods: Patients were included in this study if they had physician-diagnosed RA as well as DNA, serum, and a
date-matched clinical assessment (n= 274). Anti-PAD4 and anti-CCP antibodies were measured by immunoprecipitation
and ELISA, respectively; shared epitope (SE) status was determined by HLA-DRβ1 genotyping. Logistic regression analysis
was used to evaluate associations of smoking with PAD4 antibodies, with adjustment for relevant demographic and
clinical features. Stratified analyses by disease duration and shared epitope status were also performed.
Results: Anti-PAD4 antibodies were present in 25% of RA patients, with 50% of these individuals having anti-PAD3/4
cross-reactive antibodies. Anti-PAD4 antibodies were significantly associated with a longer disease duration, SE alleles,
and anti-CCP antibodies. Importantly, there were no significant differences in smoking history between anti-PAD4
positive and negative groups in univariate analyses, stratified analyses, or multivariable models. However, an inverse
relationship between smoking and anti-PAD4 antibodies was suggested by a lower prevalence of current smokers
among patients with anti-PAD3/4 antibodies compared to antibody negative individuals (p = 0.04). Further, the lowest
levels of anti-PAD4 antibodies were observed in current smokers (p = 0.14), and a significant association of SE
and anti-PAD4 antibodies was only present among never smokers (p = 0.01).
Conclusions: Smoking history was not associated with anti-PAD4 antibodies in patients with RA. The finding
that anti-PAD4 antibodies were not associated with smoking suggests that other environmental factors may
contribute to the development of autoimmunity to PAD4 in these patients.
Keywords: Rheumatoid arthritis, Smoking, PAD enzymes, Shared epitope, CCP
* Correspondence: edarrah1@jhmi.edu
†Equal contributors
1Division of Rheumatology, The Johns Hopkins School of Medicine,
Baltimore, MD 21224, USA
Full list of author information is available at the end of the article
© The Author(s). 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Cappelli et al. Arthritis Research & Therapy  (2018) 20:59 
https://doi.org/10.1186/s13075-018-1533-z
Background
Identifying the environmental triggers of autoimmune
disease has been a focus of research for many decades.
In rheumatoid arthritis (RA), a prototypic systemic auto-
immune disease, several environmental exposures have
been posited to contribute to disease pathogenesis
including cigarette smoking, microbial infection, and
microbiome alteration [1]. In predisposed individuals,
these environmental stimuli have been proposed to in-
duce inflammation at extra-articular sites such as the
lung and gingiva, respectively, breaking immune toler-
ance to self-antigens ultimately targeted in RA [2]. Not-
ably, anti-citrullinated protein antibodies (ACPAs),
hallmark serological findings in patients with RA, have
been found in the lungs of at-risk individuals prior to
the onset of arthritis and are enriched in gingival crevic-
ular fluid from patients with periodontitis [3, 4].
Smoking is the most widely studied environmental risk
factor linked to RA development and prognosis [5, 6].
One way that smoking is potentially linked to RA patho-
genesis is through its association with the development
of ACPAs [7–9], detected by the anti-cyclic citrullinated
peptide (CCP) clinical assay. In some studies, the associ-
ation of anti-CCP antibodies and smoking was most pro-
nounced in patients who harbored one or more MHC
class II shared epitope (SE) allele associated with RA de-
velopment [10–12]. Smoking has also been associated
with more severe disease manifestations in patients with
RA, most notably increased risk of interstitial lung dis-
ease (ILD). Patients with SE alleles [13] and those sero-
positive for RF or anti-CCP antibodies were more likely
to have ILD if they smoked [14]. In addition, several
studies have demonstrated that smoking correlates with
higher RA disease activity and higher levels of inflamma-
tory cytokines [15, 16].
The citrullinated protein targets of ACPA are gener-
ated by the peptidylarginine deiminase (PAD) enzyme
family. In humans, there are five PAD isoenzymes,
PAD 1, 2, 3, 4, and 6. PAD2 and PAD4 have been
most strongly implicated in RA pathogenesis due to
their ability to generate the citrullinated autoantigens
targeted by ACPAs, and their enrichment in the syno-
via of patients with RA [17, 18]. Increased PAD en-
zyme expression and accumulation of citrullinated
proteins has also been observed in the lungs of
chronic smokers in the absence of RA, suggesting in-
creased PAD enzyme activity as a potential patho-
physiological link between smoking and ACPA
development. Importantly, antibodies to the PAD4 en-
zyme are found in approximately 35% of patients with
RA and are associated with anti-CCP, disease duration
and erosive joint disease in several cohort studies
[19–21]. Anti-PAD4 antibodies were found less fre-
quently in early RA cohorts with 1.4% of at-risk
individuals, 18% of patients in the pre-clinical phase,
and 21% of patients with disease duration less than
two years being seropositive [20]. This suggests a
model whereby anti-PAD4 antibodies are not domin-
ant initiators of disease, but rather are important am-
plifiers of disease severity in a subset of patients with
RA. This is supported by the recent discovery of a
subgroup of patients who harbor anti-PAD4 anti-
bodies that cross-react with the related isoenzyme
PAD3 (designated as anti-PAD3/4 antibodies) [22, 23].
Patients with anti-PAD3/4 antibodies had the longest
disease duration and most severe and progressive ero-
sive joint disease compared to antibody-negative
groups [23]. Furthermore, anti-PAD3/4 antibodies had
the unique ability to activate the PAD4 enzyme in
vitro, enhancing the generation of citrullinated pro-
teins. In a follow-up study, these autoantibodies were
found to be associated with the presence of ILD, a
risk that was augmented by a history of smoking [24].
Despite the known independent associations of anti-
PAD4 autoantibodies and smoking with RA disease
severity, ILD, and ACPAs, it is unknown if cigarette
smoking is etiologically linked to the development of
anti-PAD4 antibodies. Identification of environmental
stimuli that drive the generation of anti-PAD4 antibodies
is important to define mechanisms that promote disease
evolution. Further, clinical intervention directed at modi-
fiable risk factors may prevent the development of these
potentially pathogenic autoantibodies. Therefore, this
study was designed to systematically test the hypothesis
that smoking is an important environmental trigger for




Patients were drawn from a RA cohort followed at
the Johns Hopkins Arthritis Center (IRB # 00040493)
who had physician-diagnosed RA, were 18 years of
age or older, had a DNA sample available, and had a
serum sample available from the same day as a clin-
ical assessment (n = 274).
Patient and physician data were evaluated from the
same date as available serum. Patient-reported data in-
cluding global disease activity visual analog scale (VAS)
and smoking history was collected by questionnaire.
Smoking history was categorized as current, former, or
never by patient report. The composite clinical disease
activity index (CDAI) was available on all patients. Data
about radiographic erosions was collected from chart re-
view; erosive disease was designated in a binary fashion
based on the presence or absence of any bone erosions
on radiograph review or radiologist report.
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Anti-PAD antibody assays
Immunoprecipitation assays were used to test for anti-
PAD4 and anti-PAD3/4 antibody positivity, as previously
described [23, 25]. Briefly, S35-labeleld PAD4 protein
was generated by in vitro transcription and translation
(Promega) and was incubated with patient sera for 1 h
at 4 °C. Antibodies were then isolated by protein A-
agarose beads (Pierce) and immunoprecipitated PAD4
was visualized by radiography. Anti-PAD4 positive sam-
ples were evaluated for antibody cross-reactivity to
PAD3 using a similar protocol by incubating sera with
S35-labeleld in vitro transcribed and translated PAD3.
The amount of immunoprecipitated PAD3 or PAD4 was
quantified by densitometry and normalized to a known
anti-PAD3/4 antibody positive serum to calculate anti-
PAD antibody arbitrary units.
Anti-cyclic citrullinated peptide (CCP) antibody assays
Anti-CCP antibodies were measured in sera using the
QUANTA Lite® CCP3 IgG ELISA (iNova Diagnostics).
Measurements were made using sera from the same date
as anti-PAD antibody testing, and positivity was deter-
mined based on manufacturer’s instructions (negative <
20, weak positive = 20–39, moderate positive = 40–59,
and strong positive ≥60).
Evaluation for Shared Epitope alleles
High-resolution HLA-DRβ1 genotyping was performed
on DNA from each patient by next generation sequen-
cing at the Johns Hopkins Immunogenetics Laboratory.
Briefly, HLA-typing was performed with the TruSight
HLA Sequencing Panel (illumina®, San Diego, CA). PCR
primers were used to generate long range amplicons.
Post PCR products were enzymatically cleaved and each
fragment was end labeled. Automated paired end
sequencing by synthesis was performed on the MiSeq
System. HLA types were assigned using the Assign
TruSight HLA Analysis software. HLA-DRβ1*0101,
0102, 0401, 0404, 0405, 0408, 1001, 1402 were desig-
nated as SE alleles [24].
Statistical analysis
Summary statistics were calculated for the three groups
of patients: anti-PAD4 antibody negative, anti-PAD4
mono-reactive antibody positive, and anti-PAD3/4 cross-
reactive antibody positive. Wilcoxon rank sum tests were
used to evaluate differences in continuous variables be-
tween groups; chi-square tests were used to evaluate the
categorical variables. Levels of anti-PAD-4 antibodies
were compared between smoking status groups for those
positive for anti-PAD4 antibodies graphically with box
plots and with one way ANOVA. Logistic regression was
used to determine the association between demographic
or clinical variables and PAD4 antibody serologic status
in univariate and multivariate models, yielding odds
ratios and related confidence intervals. Stratified
analyses were performed to evaluate for differing
associations between smoking and PAD4 antibodies in
subgroups, defined by gender, disease duration and
shared epitope status. The relationship between
shared epitope and anti-PAD4 antibodies was also in-
vestigated in stratified analyses according to smoking
status and disease duration.
Results
Among 274 patients in this cohort of established RA, 68
(24.8%) had anti-PAD4 antibodies. Of these, 34 (50%)
had anti-PAD4 autoantibodies that cross-reacted with
PAD3, for an overall frequency of 12.4%. Demographic
and clinical features were evaluated in patients without
PAD4 antibodies, those with anti-PAD4 mono-reactive
antibodies, and those with anti-PAD3/4 cross-reactive
antibodies (Table 1). Pair-wise comparisons yielded no
significant differences in sex, race, or age distribution
between the three groups. On average, patients were in
their 50s, were majority Caucasian, and more likely to
be female than male.
The percentage of patients with anti-CCP antibodies
and median disease duration were identical among
patients who were positive for anti-PAD4 mono-reactive
antibodies and those with PAD3/4 cross-reactive anti-
bodies. Patients in these groups were more likely to be
anti-CCP positive and had a median disease duration 9.5-
years longer than those without PAD antibodies (p < 0.01
for both). Patients with PAD4 mono-reactive antibodies
were also significantly more likely to have one or more SE
allele than those without PAD antibodies (p < 0.01). There
was a higher prevalence of erosive disease in patients with
anti-PAD3/4 antibodies (p = 0.02), but this group had a
53% lower median clinical disease activity index (CDAI) at
the time of clinical examination, when compared to anti-
PAD4 negative individuals (p = 0.04). Interestingly, there
were significantly fewer current smokers in the anti-
PAD3/4 positive group compared to those without PAD4
antibodies (0% vs. 12% respectively, p = 0.04).
Considering the demographic and clinical similarities
among people in the anti-PAD4 mono-reactive and anti-
PAD3/4 cross-reactive antibody positive subgroups,
these patients were combined into a single “anti-PAD4
positive” group for subsequent analyses exploring the
link between having any anti-PAD4 antibodies and
smoking. To further define the relationship between
smoking and anti-PAD4 antibodies, the level of PAD4
antibodies in those individuals who were anti-PAD4
seropositive was evaluated according to smoking history
(Fig. 1). Current smokers had a median anti-PAD4 anti-
body level of 0.35 units (IQR 0.07–0.42), former smokers
had a median of 0.75 units (IQR 0.45–1.16), and the
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median level in never smokers was 0.58 (IQR 0.24–0.91)
(Fig. 1). Though median anti-PAD4 units were lowest in
current smokers, differences between the groups were
not statistically significant (p = 0.14).
Univariate associations between clinical variables and
PAD4 antibody status were evaluated between patients
with and without anti-PAD4 autoantibodies (Table 2)
and revealed no significant associations between smok-
ing history and PAD4 antibodies in unadjusted analyses.
In contrast, patients who possessed one or more SE al-
lele had a 2.4-fold increase in odds of having PAD4 anti-
bodies, and those with RA disease duration greater than
10 years were more likely to have PAD4 antibodies by a
factor of 3.6 (p < 0.01 for both). In addition, patients
who were anti-CCP positive were 5.2-times more likely
to have anti-PAD4 antibodies (p < 0.01). In a multivari-
able model including potential risk factors for PAD4
antibody development, that is, sex, race, smoking status,
SE status and disease duration, the presence of SE and
disease duration greater than 10 years both remained
significantly associated with PAD4 antibodies. Smoking
history, however, remained unassociated with PAD4
antibodies in the multivariable model (Table 2).
Due to the strong association of anti-PAD4 antibodies
with SE and disease duration in univariate and multiva-
riate analyses (Table 2), stratified analyses were per-
formed to examine the influence of smoking history on
these relationships (Table 3). In subgroups with a disease
duration less than or greater than 10 years, there was no
significant association between smoking history and pre-
sence of PAD4 antibodies. Even among patients with early
RA (i.e. disease duration less than two years), where a his-
tory of smoking may be temporally closer to antibody
development, smoking remained unassociated with PAD4
antibodies (n = 34, OR = 0.20 [0.02–2.05], p = 0.18). In those
with one or more SE alleles, smoking history was associated
with a decreased odds of having PAD4 antibodies, but this
was not statistically significant (OR = 0.7 [0.3–1.3]; p = 0.25).
Table 1 Demographic and clinical features of patients with RA according to Anti-PAD antibody status
PAD negative (P0)
(N = 206)










Female sex- N (%) 163 (79%) 27 (79%) 28 (82%) 0.99 0.66 0.76
Race- N (%) 0.99 0.91 0.95
Caucasian 165 (80%) 28 (82.4%) 27 (79%)
African American 27 (13%) 4 (11.8%) 4 (12%)
Asian/Other 14 (7%) 2 (6%) 3 (9%)
Age- median (IQR) 57 (49–66) 55 (47–68) 51.5 (46–64) 0.70 0.14 0.33
Disease duration (yrs) - median (IQR) 6 (2–12) 15.5 (8–27) 15.5 (7–26) < 0.01 < 0.01 0.77
Ever smoking- N (%) 95 (47%) 16 (47%) 12 (35%) 0.96 0.22 0.32
Current smoking- N (%) 24 (12%) 3 (8.8%) 0 (0%) 0.62 0.04 0.08
CCP positive- N (%) 116 (57%) 30 (88.2%) 30 (88.2%) < 0.01 < 0.01 1.0
Shared Epitope- N (%) 112 (54%) 28 (82.4%) 22 (64.7%) < 0.01 0.26 0.10
Erosions- N (%)
N = 268
88 (43%) 17 (54.8%) 22 (65%) 0.24 0.02 0.42
CDAI- median (IQR) 7.9 (3–16) 7 (2.8–11.5) 3.7 (1.5–9.5) 0.37 0.04 0.21
On a DMARD- N (%) 184 (90%) 28 (82%) 28 (82%) 0.21 0.20 1.0
On methotrexate- N (%) 127 (63%) 20 (59%) 24 (71%) 0.73 0.33 0.31
On a biologic- N (%) 89 (44%) 17 (50%) 16 (47%) 0.49 0.71 0.81
Fig. 1 Anti-PAD4 antibody units in patients with positive tests by
smoking status. Anti-PAD4 antibody units for the 68 anti-PAD4 positive
patients, grouped by smoking history, are shown. The median anti-PAD4
level, interquartile range, and outliers are indicated in box plots for never
(n= 40), former (n= 25), and current smokers (n= 3)
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To understand if smoking history or disease duration
influenced the development of anti-PAD4 antibodies in
patients with SE alleles, these relationships were further
examined in stratified analyses (Table 4). Interestingly,
there was a significant association between having SE al-
leles and developing PAD4 antibodies in never smokers
(OR = 2.7 [1.2–6.0]; p = 0.01) (Table 4), but not in individ-
uals who had a history of smoking. A similar risk of devel-
oping anti-PAD4 antibodies among SE-positive individuals
was also observed in those with a disease duration greater
than 10 years (OR = 2.7 [1.1–6.4]; p = 0.03).
Discussion
In this cross-sectional study of patients with RA, smoking
history was not associated with having anti-PAD4 anti-
bodies or the anti-PAD3/4 cross-reactive antibody subset.
This lack of association persisted when controlling for
potentially confounding factors in multivariable and strati-
fied analyses. These findings were contrary to our hypoth-
esis and suggested a possible inverse relationship between
smoking and the development of anti-PAD4 antibodies.
This is supported by the findings that there were no
current smokers among patients with anti-PAD3/4 anti-
bodies and that current smokers had the lowest levels of
anti-PAD4 antibodies. In addition, there was a significant
association between SE and anti-PAD4 antibody develop-
ment only in never smokers, but not in those with a his-
tory of smoking. This study also confirmed previously
observed associations of anti-PAD4 and anti-PAD3/4 anti-
bodies with longer disease duration and anti-CCP anti-
bodies [19, 20, 23, 26]. Taken together, these results
suggest that environmental factors, other than cigarette
smoking, may drive the development of anti-PAD4 anti-
bodies in patients with RA.
This is the first study to systematically evaluate the
relationship between smoking and the development of
anti-PAD4 and anti-PAD3/4 antibodies in patients with
RA. Although not previously appreciated, detailed review
of clinical data from several published RA studies suggests
a persistently lower smoking history among patients with
anti-PAD4 or anti-PAD3/4 antibodies. Borderline and sig-
nificant inverse associations of anti-PAD4 antibodies with
a history of ever smoking were observed in indigenous
North American (p = 0.067) [20] and primarily Caucasian
(p = 0.016) [23] RA cohorts, respectively. Furthermore, in
the two published studies of anti-PAD3/4 antibodies,
current smokers were less prevalent in the anti-PAD3/4
antibody positive group compared to those without anti-
PAD antibodies (0% vs. 16%; p = 0.075 and 15% vs.
33%; p = 0.13) [24, 25]. These data bolster the findings
of our current study and strongly suggest that smok-
ing is not the trigger of anti-PAD4 antibody develop-
ment in patients with RA.
These findings are surprising given the strong associ-
ation of anti-PAD4 antibodies and anti-CCP observed in
this and published studies, as well as the widely accepted
relationship between smoking and anti-CCP develop-
ment [19, 20, 23, 25–27]. However, although initial
studies suggested an association of smoking history with
ACPA development, more recent studies focusing on
isotypes of anti-CCP antibodies and specific ACPAs have
painted a more complex picture [28]. For example, in
one study of patients with RA, smoking was not associ-
ated with anti-CCP, citrullinated vimentin or citrulli-
nated fibrinogen antibodies, but was associated with
Table 2 Associations between demographic and clinical variables and presence of anti-PAD4 antibodies
Univariate Models Multivariable Model*
Variable OR (95% CI) p-value OR (95% CI) p-value
Female sex 1.1 (0.6–2.2) 0.74 0.9 (0.4–1.9) 0.74
Non-Caucasian Race 1.0 (0.5–1.9) 0.87 1.5 (0.7–3.2) 0.34
Ever Smoker 0.8 (0.5–1.4) 0.46 0.8 (0.4–1.4) 0.41
Disease duration > 10 years 3.6 (2.0–6.5) < 0.01 3.5 (1.9–6.3) < 0.01
Presence of Shared epitope 2.4 (1.3–4.3) < 0.01 2.3 (1.2–4.5) 0.02
OR odds ratio, CI confidence interval; *model adjusted for disease duration, SE, race, smoking status, and sex
Table 3 Associations between anti-PAD4 antibody presence
and ever smoking in stratified analyses
Variable OR (95% CI) p-value
With Shared Epitope 0.7 (0.3–1.3) 0.25
No Shared Epitope 0.9 (0.3–2.6) 0.90
Duration > 10 0.9 (0.4–1.9) 0.75
Duration < 10 0.8 (0.3–2.0) 0.66
OR Odds ratio from univariate logistic regression, CI confidence interval
Table 4 Associations between anti-PAD4 antibody presence
and shared epitope in stratified analyses
Variable OR (95% CI) p-value
In Ever Smokers 2.0 (0.8–5.1) 0.16
In Never Smokers 2.7 (1.2–6.0) 0.01
Duration > 10 2.7 (1.1–6.4) 0.03
Duration < 10 1.5 (0.6–3.6) 0.40
OR Odds ratio from univariate logistic regression, CI confidence interval
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citrullinated alpha-enolase peptide antibodies [29].
Another recent study demonstrated that only IgG2 and
IgA isotypes of anti-CCP antibodies associated with
smoking, while IgG1 and IgG4 anti-CCP antibodies were
associated with having SE [30]. These findings suggest
that the relationship between smoking, citrullination,
and the autoantibody response in RA is more nuanced
than previously appreciated.
Understanding how specific environmental stimuli
affect the nature of the ACPA response and subsequent
development of anti-PAD4 antibodies is important to
define environmental factors that drive disease propaga-
tion and amplification. The association of anti-PAD4
antibodies with disease duration suggests the presence
of persistent drivers of inflammation that may contribute
to the evolution of the autoantibody response and subse-
quent generation of PAD4-activating autoantibodies.
These data also may inform the interpretation of the
previously observed increased risk of RA-associated ILD
in patients with anti-PAD3/4 antibodies and a history of
smoking [24]. Rather than smoking being the causal fac-
tor for the development of anti-PAD3/4 antibodies and
subsequent ILD, one interpretation of the present find-
ings is that of a two-hit model. In this scenario, two in-
dependently occurring factors (i.e. smoking and anti-
PAD3/4 antibodies) synergize to induce ILD. This model
is speculative and requires further studies to: 1) validate
the link between anti-PAD3/4 antibodies and ILD; and
2) determine if these antibodies can directly perpetuate
lung damage in patients with RA.
These results implicate environmental factors other
than smoking in anti-PAD4 antibody development,
perhaps through important interactions with SE alleles. In
this regard, anti-Porphyromonas gingivalis (Pg) antibodies
were associated with non-smoking status in a recent
French cohort of patients with early RA [31], and ACPAs
were shown to be associated with SE alleles only in
patients who had a previous exposure to Aggregatibacter
actinomycetemcomitans (Aa) [32], a bacterium linked to
periodontitis. This work also demonstrated that leuko-
toxin A, a membranolytic toxin expressed by Aa, induces
potent activation of the PAD enzymes resulting in hyper-
citrullination of known RA autoantigens, thus linking
periodontal infection to ACPA development [32]. Given
the association of both anti-PAD4 antibodies and anti-Pg
antibodies with non-smoking status in patients with RA,
and association of Aa with PAD enzyme activation,
periodontal disease and resulting immune responses could
play important roles in the development of anti-PAD4
antibodies. Exploring this mechanistic link is a key area
for future research.
There are important outstanding questions that were
not addressed in the current study including the inter-
action between smoking and anti-PAD4 antibodies in
patients with early RA and their relationship to ILD
development. Patients in this cohort had long-standing
RA that was generally well-controlled with treatment, so
those with early RA or poorly-controlled disease were
underrepresented, and clinical information regarding the
presence of ILD was not available. In addition, several
subanalyses were performed as a mechanism to control
for potential confounders and ensure that an association
of anti-PAD4 antibodies with smoking in important
patient subgroups was not overlooked. While this
strengthened the conclusion that smoking is not linked
to anti-PAD4 development, multiple subanalyses have
the caveat of reducing the sample size and thus the
power to determine positive associations. Future studies
are needed to determine if these results are applicable to
other cohorts including early RA patients and those with
ILD. Lastly, this study was cross-sectional with anti-
PAD4 antibody testing performed at a single point in
time, so could not capture future anti-PAD4 antibody
development in these individuals. Since these antibodies
are associated with disease duration, a follow-up study
measuring seroconversion to anti-PAD4 antibody posi-
tivity over time in a longitudinal cohort may reveal novel
information regarding the relationship between environ-
mental factors and anti-PAD4 antibody development.
Conclusions
This study demonstrated that anti-CCP, SE alleles, and
disease duration, but not a history of smoking, were
associated with anti-PAD4 antibodies in patients with
RA. Further efforts aimed at defining the inciting envir-
onmental stimuli linked to the development of anti-
PAD4 in RA patients are warranted and may reveal
important insights into disease mechanism. Defining the
environmental factors associated with the generation of
anti-PAD4 and anti-PAD3/4 antibodies may also identify
novel targets for therapeutic intervention to prevent the
generation of these potentially disease-amplifying auto-
antibodies in patients with RA.
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